Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 7 | 2018 | 568 | 1.450 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2018 | 1218 | 1.430 |
Why?
|
| Magnetic Resonance Imaging, Cine | 8 | 2017 | 64 | 1.410 |
Why?
|
| Myocardial Perfusion Imaging | 5 | 2015 | 24 | 1.340 |
Why?
|
| Coronary Circulation | 5 | 2015 | 30 | 1.080 |
Why?
|
| Ventricular Function, Left | 6 | 2017 | 194 | 0.990 |
Why?
|
| Stroke Volume | 6 | 2018 | 278 | 0.930 |
Why?
|
| Dobutamine | 3 | 2018 | 43 | 0.810 |
Why?
|
| Myocardium | 4 | 2016 | 170 | 0.750 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 546 | 0.740 |
Why?
|
| Anthracyclines | 5 | 2018 | 51 | 0.690 |
Why?
|
| Myocardial Ischemia | 2 | 2018 | 83 | 0.660 |
Why?
|
| Heart | 2 | 2018 | 161 | 0.620 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 54 | 0.610 |
Why?
|
| Predictive Value of Tests | 10 | 2018 | 787 | 0.590 |
Why?
|
| Coronary Vessels | 2 | 2014 | 147 | 0.580 |
Why?
|
| Hemodynamics | 3 | 2017 | 148 | 0.540 |
Why?
|
| Myocardial Infarction | 4 | 2019 | 412 | 0.530 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 39 | 0.520 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2014 | 3 | 0.520 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 22 | 0.520 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 55 | 0.520 |
Why?
|
| Cardiomegaly | 1 | 2014 | 30 | 0.510 |
Why?
|
| Prediabetic State | 1 | 2015 | 54 | 0.500 |
Why?
|
| Dipyridamole | 1 | 2013 | 2 | 0.480 |
Why?
|
| Purines | 1 | 2013 | 16 | 0.470 |
Why?
|
| Adenosine | 1 | 2013 | 41 | 0.470 |
Why?
|
| Pyrazoles | 1 | 2013 | 64 | 0.460 |
Why?
|
| Cardiovascular System | 1 | 2013 | 39 | 0.460 |
Why?
|
| Vasodilation | 1 | 2013 | 87 | 0.450 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2018 | 136 | 0.430 |
Why?
|
| Risk Factors | 12 | 2018 | 3531 | 0.420 |
Why?
|
| Heart Ventricles | 3 | 2018 | 107 | 0.420 |
Why?
|
| Female | 23 | 2019 | 18164 | 0.400 |
Why?
|
| Lung | 1 | 2012 | 233 | 0.390 |
Why?
|
| Risk Assessment | 6 | 2019 | 1305 | 0.380 |
Why?
|
| Male | 21 | 2019 | 17807 | 0.360 |
Why?
|
| Contrast Media | 3 | 2015 | 123 | 0.360 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 25 | 0.360 |
Why?
|
| Humans | 27 | 2019 | 29093 | 0.360 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2009 | 21 | 0.360 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 1013 | 0.350 |
Why?
|
| Hospital Mortality | 2 | 2019 | 186 | 0.330 |
Why?
|
| Middle Aged | 17 | 2019 | 10829 | 0.310 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2018 | 62 | 0.300 |
Why?
|
| Coronary Angiography | 2 | 2019 | 136 | 0.280 |
Why?
|
| Aged | 14 | 2019 | 9487 | 0.270 |
Why?
|
| Ventricular Remodeling | 2 | 2016 | 52 | 0.270 |
Why?
|
| Anemia | 1 | 2005 | 55 | 0.270 |
Why?
|
| Age Factors | 4 | 2018 | 1108 | 0.260 |
Why?
|
| Electrocardiography | 2 | 2019 | 562 | 0.250 |
Why?
|
| Heart Valve Prosthesis | 2 | 2017 | 53 | 0.240 |
Why?
|
| Survivors | 2 | 2016 | 145 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 518 | 0.220 |
Why?
|
| Neoplasms | 3 | 2018 | 610 | 0.220 |
Why?
|
| Time Factors | 9 | 2019 | 2001 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 3717 | 0.210 |
Why?
|
| Prognosis | 5 | 2019 | 1362 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 359 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 196 | 0.190 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 726 | 0.190 |
Why?
|
| Edema, Cardiac | 2 | 2016 | 13 | 0.180 |
Why?
|
| Hospitals, University | 1 | 2019 | 23 | 0.170 |
Why?
|
| Disease Management | 1 | 2019 | 114 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2018 | 67 | 0.160 |
Why?
|
| Tricuspid Valve | 1 | 2017 | 5 | 0.160 |
Why?
|
| Foramen Ovale, Patent | 1 | 2017 | 7 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2018 | 97 | 0.150 |
Why?
|
| Stents | 2 | 2010 | 171 | 0.150 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 41 | 0.150 |
Why?
|
| Cardiac Volume | 1 | 2017 | 11 | 0.150 |
Why?
|
| Thrombosis | 1 | 2017 | 60 | 0.150 |
Why?
|
| North Carolina | 3 | 2019 | 1423 | 0.150 |
Why?
|
| Bioprosthesis | 1 | 2017 | 55 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 61 | 0.150 |
Why?
|
| Chest Pain | 1 | 2019 | 175 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 48 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 863 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 430 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 105 | 0.130 |
Why?
|
| Gadolinium | 1 | 2015 | 18 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 12 | 0.130 |
Why?
|
| Simvastatin | 1 | 2014 | 25 | 0.130 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 10 | 0.130 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 28 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2015 | 54 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2015 | 72 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 28 | 0.120 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 138 | 0.120 |
Why?
|
| Pyrroles | 1 | 2014 | 55 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 64 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2015 | 454 | 0.120 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 64 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2013 | 61 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 126 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2014 | 211 | 0.110 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 13 | 0.110 |
Why?
|
| Sex Factors | 1 | 2015 | 631 | 0.110 |
Why?
|
| Registries | 2 | 2019 | 278 | 0.110 |
Why?
|
| Ethnic Groups | 1 | 2015 | 440 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2015 | 466 | 0.110 |
Why?
|
| Heart Rate | 1 | 2013 | 315 | 0.100 |
Why?
|
| Exercise Test | 3 | 2019 | 194 | 0.100 |
Why?
|
| Adult | 7 | 2018 | 8420 | 0.100 |
Why?
|
| Young Adult | 2 | 2017 | 2402 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2018 | 2019 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2010 | 14 | 0.090 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2010 | 32 | 0.090 |
Why?
|
| Obstetric Labor Complications | 1 | 2009 | 12 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2009 | 29 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 82 | 0.090 |
Why?
|
| Bacteremia | 1 | 2009 | 53 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2015 | 693 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3111 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2009 | 120 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 666 | 0.080 |
Why?
|
| Animals | 2 | 2013 | 7297 | 0.080 |
Why?
|
| New York | 1 | 2007 | 18 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 881 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2108 | 0.080 |
Why?
|
| Creatinine | 1 | 2007 | 174 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 293 | 0.070 |
Why?
|
| Pregnancy | 1 | 2009 | 815 | 0.070 |
Why?
|
| Fibrosis | 2 | 2016 | 102 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2005 | 29 | 0.070 |
Why?
|
| Logistic Models | 1 | 2007 | 727 | 0.070 |
Why?
|
| Disease Progression | 2 | 2018 | 572 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 795 | 0.060 |
Why?
|
| Cytokines | 1 | 2005 | 243 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2005 | 182 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 298 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 532 | 0.050 |
Why?
|
| Prevalence | 2 | 2015 | 896 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1356 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1119 | 0.050 |
Why?
|
| Troponin | 1 | 2019 | 79 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3099 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2018 | 74 | 0.040 |
Why?
|
| Septal Occluder Device | 1 | 2017 | 4 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2017 | 87 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2019 | 364 | 0.040 |
Why?
|
| United States | 2 | 2016 | 3630 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 493 | 0.040 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 175 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 90 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 29 | 0.040 |
Why?
|
| Hospitalization | 1 | 2018 | 417 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2015 | 70 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 226 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 637 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 540 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 66 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 281 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 238 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 25 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2014 | 187 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 720 | 0.030 |
Why?
|
| Pyridines | 1 | 2010 | 78 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 235 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 525 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 464 | 0.020 |
Why?
|